Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Income (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Income for 16 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 92.21% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$901000.0 through Dec 2025, up 98.11% year-over-year, with the annual reading at -$901000.0 for FY2025, 98.11% up from the prior year.
  • Net Income for Q4 2025 was -$1.5 million at Anika Therapeutics, down from $846000.0 in the prior quarter.
  • The five-year high for Net Income was $14.7 million in Q4 2023, with the low at -$28.1 million in Q3 2024.
  • Average Net Income over 5 years is -$2.2 million, with a median of -$2.0 million recorded in 2024.
  • Peak annual rise in Net Income hit 462.04% in 2022, while the deepest fall reached 848.21% in 2022.
  • Over 5 years, Net Income stood at -$3.3 million in 2021, then soared by 462.04% to $11.8 million in 2022, then grew by 24.22% to $14.7 million in 2023, then tumbled by 232.02% to -$19.4 million in 2024, then surged by 92.21% to -$1.5 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$1.5 million, $846000.0, and $677000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.